These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 37161343

  • 1. Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.
    Wang J, Zhao M, Han G, Han X, Shi J, Mi L, Li N, Yin X, Duan X, Hou J, Yin F.
    Technol Cancer Res Treat; 2023; 22():15330338231166765. PubMed ID: 37161343
    [Abstract] [Full Text] [Related]

  • 2. Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.
    Zhao S, Zhou M, Wang P, Yang J, Zhang D, Yin F, Song P.
    Technol Cancer Res Treat; 2022; 21():15330338221133640. PubMed ID: 36259214
    [Abstract] [Full Text] [Related]

  • 3. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
    Wang YY, Yang X, Wang YC, Long JY, Sun HS, Li YR, Xun ZY, Zhang N, Xue JN, Ning C, Zhang JW, Zhu CP, Zhang LH, Yang XB, Zhao HT.
    World J Gastroenterol; 2023 Mar 14; 29(10):1614-1626. PubMed ID: 36970591
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma.
    Xin Y, Zhang X, Liu N, Peng G, Huang X, Cao X, Zhou X, Li X.
    Hepatol Int; 2023 Jun 14; 17(3):753-764. PubMed ID: 37038024
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis.
    Chen Y, Jia L, Li Y, Cui W, Wang J, Zhang C, Bian C, Luo T.
    Front Immunol; 2024 Jun 14; 15():1466113. PubMed ID: 39281676
    [Abstract] [Full Text] [Related]

  • 6. The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study.
    Ding Z, Fang G, Tang Y, Zeng Y.
    Sci Rep; 2024 Jun 21; 14(1):14334. PubMed ID: 38906915
    [Abstract] [Full Text] [Related]

  • 7. A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma.
    Teng Y, Ding X, Li W, Sun W, Chen J.
    Technol Cancer Res Treat; 2022 Jun 21; 21():15330338221075174. PubMed ID: 35313780
    [Abstract] [Full Text] [Related]

  • 8. Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-A Retrospective Study.
    Chen Y, Jia L, Li Y, Cui W, Wang J, Zhang C, Bian C, Wang Z, Lin D, Luo T.
    Ann Surg Oncol; 2024 Nov 21; 31(12):7860-7869. PubMed ID: 39090499
    [Abstract] [Full Text] [Related]

  • 9. The treatment of transarterial chemoembolization/hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor is effective against hepatocellular carcinoma with portal vein tumor thrombus: A systematic review.
    Yuanren G, Yin L, Liu R, Cui Y.
    Front Oncol; 2023 Nov 21; 13():1054072. PubMed ID: 36969065
    [Abstract] [Full Text] [Related]

  • 10. Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study.
    Guo P, Pi X, Gao F, Li Q, Li D, Feng W, Cao W.
    Front Oncol; 2022 Nov 21; 12():945915. PubMed ID: 36338683
    [Abstract] [Full Text] [Related]

  • 11. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
    Zou X, Xu Q, You R, Yin G.
    Cancer Med; 2023 May 21; 12(10):11315-11333. PubMed ID: 36951443
    [Abstract] [Full Text] [Related]

  • 12. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X, Sun W, Li W, Shen Y, Guo X, Teng Y, Liu X, Zheng L, Li W, Chen J.
    Cancer; 2021 Oct 15; 127(20):3782-3793. PubMed ID: 34237154
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lin LW, Yan LY, Ke K, Yang WZ, Lin JQ, Huang N.
    Brachytherapy; 2023 Oct 15; 22(6):858-871. PubMed ID: 37574351
    [Abstract] [Full Text] [Related]

  • 14. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.
    Chen S, Wu Z, Shi F, Mai Q, Wang L, Wang F, Zhuang W, Chen X, Chen H, Xu B, Lai J, Guo W.
    J Cancer Res Clin Oncol; 2022 Aug 15; 148(8):2115-2125. PubMed ID: 34453221
    [Abstract] [Full Text] [Related]

  • 15. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.
    Cai M, Huang W, Huang J, Shi W, Guo Y, Liang L, Zhou J, Lin L, Cao B, Chen Y, Zhou J, Zhu K.
    Front Immunol; 2022 Aug 15; 13():848387. PubMed ID: 35300325
    [Abstract] [Full Text] [Related]

  • 16. Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study.
    Jiang N, Zhong B, Huang J, Li W, Zhang S, Zhu X, Ni C, Shen J.
    Front Immunol; 2023 Aug 15; 14():1205636. PubMed ID: 37583693
    [Abstract] [Full Text] [Related]

  • 17. Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.
    Zhang JX, Hua HJ, Cheng Y, Liu S, Shi HB, Zu QQ.
    Acad Radiol; 2024 Apr 15; 31(4):1304-1311. PubMed ID: 37775449
    [Abstract] [Full Text] [Related]

  • 18. Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma.
    Sheng Y, Wang Q, Liu H, Wang Q, Chen W, Xing W.
    Br J Radiol; 2024 Feb 28; 97(1155):668-679. PubMed ID: 38303541
    [Abstract] [Full Text] [Related]

  • 19. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.
    Zhang JX, Cheng Y, Wei J, Fan WL, Liu J, Zhou CG, Liu S, Shi HB, Chu XY, Zheng WL, Zu QQ.
    Cardiovasc Intervent Radiol; 2024 Jun 28; 47(6):751-761. PubMed ID: 38671322
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization.
    Lin LW, Ke K, Yan LY, Chen R, Huang JY.
    Front Oncol; 2023 Jun 28; 13():1178428. PubMed ID: 37207144
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.